Kiniksa Pharmaceuticals International (KNSA) Competitors

$63.95 +1.54 (+2.47%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$63.92 -0.04 (-0.05%)

As of 06/30/2026 05:55 PM Eastern

KNSA vs. ASND, GMAB, BBIO, RDY, and AXSM

Should you buy Kiniksa Pharmaceuticals International stock or one of its competitors? MarketBeat compares Kiniksa Pharmaceuticals International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiniksa Pharmaceuticals International include Ascendis Pharma A/S (ASND), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Dr. Reddy's Laboratories (RDY), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Kiniksa Pharmaceuticals International has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.43	-$258M	$8.67	30.76
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 57.87% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Ascendis Pharma A/S presently has a consensus price target of $295.39, suggesting a potential upside of 10.75%. Kiniksa Pharmaceuticals International has a consensus price target of $62.71, suggesting a potential downside of 1.93%. Given Ascendis Pharma A/S's higher probable upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 6 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.13 beat Ascendis Pharma A/S's score of 0.73 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Kiniksa Pharmaceuticals International on 9 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Genmab A/S has a net margin of 21.05% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Genmab A/S's return on equity of 15.34% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, Genmab A/S had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Genmab A/S and 6 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.13 beat Genmab A/S's score of -0.04 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Genmab A/S currently has a consensus target price of $37.93, indicating a potential upside of 38.07%. Kiniksa Pharmaceuticals International has a consensus target price of $62.71, indicating a potential downside of 1.93%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Genmab A/S has higher revenue and earnings than Kiniksa Pharmaceuticals International. Genmab A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.60	$963M	$1.32	20.81
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Genmab A/S beats Kiniksa Pharmaceuticals International on 9 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.13 beat BridgeBio Pharma's score of 0.26 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to BridgeBio Pharma's net margin of -124.42%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	29.05	-$724.93M	-$3.74	N/A
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06

BridgeBio Pharma currently has a consensus target price of $92.90, suggesting a potential upside of 24.73%. Kiniksa Pharmaceuticals International has a consensus target price of $62.71, suggesting a potential downside of 1.93%. Given BridgeBio Pharma's higher possible upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Kiniksa Pharmaceuticals International beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Kiniksa Pharmaceuticals International has a consensus price target of $62.71, indicating a potential downside of 1.93%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

In the previous week, Kiniksa Pharmaceuticals International had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Dr. Reddy's Laboratories. Kiniksa Pharmaceuticals International's average media sentiment score of 1.13 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Dr. Reddy's Laboratories has higher revenue and earnings than Kiniksa Pharmaceuticals International. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.38	$456M	$0.58	25.01
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Axsome Therapeutics' net margin of -26.59%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus price target of $62.71, indicating a potential downside of 1.93%. Axsome Therapeutics has a consensus price target of $258.95, indicating a potential upside of 5.79%. Given Axsome Therapeutics' higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Kiniksa Pharmaceuticals International has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Axsome Therapeutics. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 5 mentions for Axsome Therapeutics. Kiniksa Pharmaceuticals International's average media sentiment score of 1.13 beat Axsome Therapeutics' score of 0.50 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Axsome Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Kiniksa Pharmaceuticals International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KNSA vs. The Competition

Export

Metric	Kiniksa Pharmaceuticals International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.80B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	71.06	20.90	27.51	24.87
Price / Sales	7.26	341.80	540.69	102.84
Price / Cash	78.63	143.77	48.53	58.59
Price / Book	8.60	8.75	11.01	6.54
Net Income	$59.01M	$23.81M	$3.57B	$336.70M
7 Day Performance	8.15%	3.60%	2.31%	2.88%
1 Month Performance	32.05%	3.72%	1.38%	0.64%
1 Year Performance	134.77%	68.80%	36.70%	31.34%

Kiniksa Pharmaceuticals International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KNSA Kiniksa Pharmaceuticals International	3.0818 of 5 stars	$63.95 +2.5%	$62.71 -1.9%	+131.1%	$4.80B	$677.56M	71.06	220	News Coverage Positive News Analyst Forecast
ASND Ascendis Pharma A/S	4.262 of 5 stars	$261.58 +9.9%	$295.39 +12.9%	+54.5%	$16.32B	$814.57M	30.17	1,189	High Trading Volume
GMAB Genmab A/S	4.6725 of 5 stars	$26.14 +1.1%	$37.93 +45.1%	+33.0%	$16.30B	$3.72B	19.80	3,029	News Coverage
BBIO BridgeBio Pharma	3.1665 of 5 stars	$69.69 +0.5%	$92.90 +33.3%	+72.5%	$13.65B	$502.08M	N/A	400
RDY Dr. Reddy's Laboratories	1.7083 of 5 stars	$15.25 +4.0%	N/A	-3.5%	$12.73B	$3.58B	26.29	27,527	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KNSA) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. ASND, GMAB, BBIO, RDY, and AXSM

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Summary

How does Kiniksa Pharmaceuticals International compare to Dr. Reddy's Laboratories?

Summary

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. ASND, GMAB, BBIO, RDY, and AXSM

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Which has higher valuation and earnings, ASND or KNSA?

Do institutionals & insiders have more ownership in ASND or KNSA?

Is ASND or KNSA more profitable?

Do analysts prefer ASND or KNSA?

Does the media prefer ASND or KNSA?

Which has more risk & volatility, ASND or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Is GMAB or KNSA more profitable?

Does the media refer more to GMAB or KNSA?

Which has more risk & volatility, GMAB or KNSA?

Do analysts recommend GMAB or KNSA?

Which has preferable valuation & earnings, GMAB or KNSA?

Do insiders & institutionals have more ownership in GMAB or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Which has more risk & volatility, BBIO or KNSA?

Does the media refer more to BBIO or KNSA?

Is BBIO or KNSA more profitable?

Do institutionals & insiders hold more shares of BBIO or KNSA?

Which has preferable valuation and earnings, BBIO or KNSA?

Do analysts prefer BBIO or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Dr. Reddy's Laboratories?

Do analysts rate RDY or KNSA?

Which has more risk and volatility, RDY or KNSA?

Does the media refer more to RDY or KNSA?

Is RDY or KNSA more profitable?

Which has better valuation and earnings, RDY or KNSA?

Do institutionals and insiders have more ownership in RDY or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Is KNSA or AXSM more profitable?

Do institutionals & insiders believe in KNSA or AXSM?

Which has more risk and volatility, KNSA or AXSM?

Do analysts recommend KNSA or AXSM?

Which has stronger valuation & earnings, KNSA or AXSM?

Does the media prefer KNSA or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools